Drugs / BPX-201
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01823978 | Apr 2013 → May 2016 | castration-resistant prostate carcinoma | Bellicum Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01823978 ↗ |
| Modality | Vaccine | “dendritic cell vaccine, BPX-201” NCT01823978 ↗ |